Trial Profile
A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Children, Adolescents and Adults in Russia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Apr 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
- Focus Therapeutic Use
- Sponsors Novartis Vaccines
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2012 New trial record